


PHARMACEUTICAL 2022

Jazz Pharmaceuticals.

Jazz Pharmaceuticals plc Rank 34 of 475








RealRate

PHARMACEUTICAL 2022





The relative strengths and weaknesses of Jazz Pharmaceuticals plc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Jazz Pharmaceuticals plc compared to the market average is the variable Net Income, increasing the Economic Capital Ratio by 224% points. The greatest weakness of Jazz Pharmaceuticals plc is the variable Other Expenses, reducing the Economic Capital Ratio by 40% points.

The company's Economic Capital Ratio, given in the ranking table, is 164%, being 441% points above the market average of -276%.

Input Variable	Value in 1000 USD
Assets, Current	2,611,334
Cost of Goods Sold	0
Intangible Assets	8,979,937
Liabilities, Current	809,303
Liabilities, Non-Current	0
Other Assets	707,368
Other Compr. Net Income	-266,008
Other Expenses	1,182,645
Other Liabilities	0
Other Net Income	-283,830
Property and Equipment	0
Research and Development	505,748
Revenues	3,094,238
Selling, General and Administrative Expense	1,451,683

Output Variable	Value in 1000 USD
Assets	12,298,639
Liabilities	809,303
Expenses	3,140,076
Stockholders Equity	11,489,336
Net Income	-329,668
Comprehensive Net Income	-462,672
Economic Capital Ratio	164%

